33 results about "Fas ligand" patented technology

Anti-Fas antibodies which are cross-reactive with mouse and human Fas and are useful in the treatment of conditions attributable to abnormalities in the Fas / Fas ligand system.

The invention provides for DNA encoding Fas ligand muteins and chimeras and the proteins encoded thereby. The invention further includes the use of DNA and vectors to produce transformed cells expressing the mutant or chimeric Fas ligand. When the Fas ligand of the invention is a non cleavable form, the cells expressing the Fas ligand are useful in vitro for identifying Fas expressing cells or in vivo for reducing populations of Fas expressing cells. Thus, in other embodiments, the present invention is also directed to a method for treating a patient, for example a mammal, for autoimmune disease or transplant rejection by administering a Fas ligand therapeutic agent. The therapeutic agent is a polypeptide, a polynucleotide encoding the polypeptide or a small molecule. The polypeptides include full-length Fas ligand polypeptide, or a biologically active variant, derivative, portion, fusion or peptide thereof.

The invention provides methods and compositions utilizing FasL armed donor graft cells to reduce or eliminate host allogeneic or xenogeneic graft rejection, and FasL armed host cells to reduce or eliminate graft versus host disease.

The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.

Preventives and remedies for diffuse lung diseases whereby apoptosis can be inhibited and thus favorable preventive / therapeutic effects can be established.These drugs contain apoptosis-inhibiting substances as the active ingredient.The above apoptosis-inhibiting substances include Fas antagonists and Fas / Fas ligand binding inhibitors such as Fas derivatives and anti-Fas ligand antibodies.

Methods and compositions are disclosed for inhibiting, deterring or preventing apoptosis of cardiac myocytes, transplanted stem cells, vascular stem cells, and vascular smooth muscle cells by means of expressing or synthesizing clusterin. Also disclosed are methods and compositions for producing recombinant clusterin, or its biologically active peptides, and for induction of clusterin-associated lipoproteins or enzymes for deterring or preventing inflammatory injury and apoptosis induced by oxLDL, oxysterols, cytokines, and Fas Ligand. Also disclosed is an induction method and composition for enhancing expression of ALDH and ALDH-associated enzymes or co-factors to prevent cytotoxicity or detoxification. Therapeutic methods providing new expression or overexpression of clusterin in vascular or cardiac tissue are expected to inhibit the formation of atherosclerotic lesions, stabilize existing atherosclerotic plaques, and repair failing or damaged cardiac tissue.

Novel bifunctional peptides useful in the treatment and / or diagnosis of EAE or MS. The peptides have a first peptide portion derived from an epitope of myelin proteolipid protein, myelin oligodendrocyte glycoprotein, or oligodendrocyte-specific peptide and a second peptide portion derived from CD11a (LFA-1 alpha subunit), CD18 (LFA-1 beta subunit), CD154 (CD40L), Fas-Ligand, or CTLA4. The carboxy and / or amino termini of the bifunctional peptides may be modified.

The MORT-1 protein, analogs thereof and fragments thereof bind with the intracellular domain of the FAS ligand receptor. DNA encoding such protein, analogs and fragments, may be used to make vectors and host cells in order to produce such proteins, analogs and fragments. The peptides may be formulated into pharmaceutical compositions for use in modulation of the FAS-R ligand effect on cells carrying a FAS-R.

The present invention provides structures of small molecules capable of modulating apoptotic cell death. More specifically, the structures relate to the structures of apoptotic active sites of mammalian alpha-fetoprotein (AFP) and albumin. Peptides mimicking the active site contain two sequences, Arg-Gly-Asp and Asp-X-X-Asp, wherein X means any amino acid. These sequences are needed in the same molecule for causing a wide range of biological activities. The peptides can be utilized to suppress apoptotic pathways by inhibiting the cytochrome c-mediated caspase activation. Thus, the peptides can be used to inhibit effects of apoptosis induced by oxidative stress, drugs, cytokines, Fas-ligand, alpha-fetoprotein, used to prevent apoptosis in culturing cells, in organ transplantation, in immunological autoimmune disorders and immunodeficiency syndrome induced by viral infection, or to diminish side cytotoxic effects after chemotherapy and radiation therapy.

Provided are fusion proteins comprising a first domain and a second domain, wherein the first domain comprises a polypeptide that binds to and triggers PD-1 and the second domain comprises a polypeptide that binds to and triggers a TRAIL receptor or Fas. In some embodiments, the polypeptide that binds to and triggers PD-1 comprises at least a portion of the extracellular domain of PD-L1 or PD-L2 and the second domain comprises at least a portion of the extracellular domain of TRAIL or Fas ligand. Also provided are methods for treating autoimmune, alloimmune or inflammatory diseases, and methods for treating cancer, using the fusion proteins.

The invention relates to a separation method for decidua basalis stem cells of a placenta, and belongs to the technical field of regenerative medicine and biology. The separation method for the decidua basalis stem cells of the placenta comprises the following steps of collecting the placenta, and soaking the placenta in a placenta preservation solution which is a basic culture medium PBS containing 1x-2xdouble antibodies and 10% high-sugar DMEM; stripping the decidua basalis and carrying out cleaning; cutting the decidua basalis into pieces, carrying out enzymolysis by using enzymatic hydrolysate a which is a DMEM high-sugar basal culture medium containing 0.25% of pancreatin and 0.02% of EDTA, carrying out centrifuging, and discarding supernate, carrying out enzymolysis by using enzymatic hydrolysate b which is a DMEM high-sugar basic culture medium containing 0.1 to 0.2 mg / mL of collagenase IV, 0.01 to 0.05 mg / mL of neutral enzyme, 5 to 10 ng / ml of a Fas ligand inhibitor and 5 to 10ng / ml of a survivin inhibitor; and carrying out subpackaging, counting and inoculating. According to the separation method for the decidua basalis stem cells of the placenta, the decidua basalis stemcells of the placenta are extracted by adopting a double-enzymolysis method, and the method is simple in operation step, high in cell acquisition rate, sufficient in extracted cell number and high incell viability. In addition, the invention aims to comprehensively extract the decidua basalis stem cells of the placenta.